Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Christopher Francis Thompson

Amjad Ali

Peter J Sinclair

Zhijian Lu

Nazia Quraishi

Cameron James Smith

Mark E Scott

Christopher J Dinsmore

Michelle R Machacek

Matthew Ernst Voss

B Wesley Trotter

Michael Hale Reutershan

Francesc Xavier Fradera Llinas

Michelle Martinez

Gayle E Taylor

Ronald J Doll

Stephane L Bogen

Manami Shizuka

David Joseph Guerin

Jason David Katz

Norman Kong

Qiaolin Deng

Peter H Fuller

Matthew Christopher

Yi-Heng Chen

Binyuan Sun

Hongbo Zeng

Danielle Falcone

Yumei Liu

Yunfeng Bai

Zhixiang Zheng

Michael D Altman

Donald W Graham

Qinglin Pu

Hong Li

Luis E Torres

Liping Yang

Julianne A Hunt

Carolyn Michele Cammarano

Neville J Anthony

James M Balkovec

Jason D Brubaker

Jianmin Fu

Matthew Lloyd Childers

Ramzi Farah Sweis

Ravi Kurukulasuriya

Florida Kallashi

Joann M Napolitano

Joann Bohn

Adrian A Dowst

Philip Jones

Scott D Edmondson

Dong-Ming Shen

Kenneth Jay Barr

Steven L Colletti

Hongjun Zhang

Dooseop Kim

Joshua Close

James R Tata

Gregori J Morriello

Cheng Zhu

Raman Kumar Bakshi

Joon Jung

XiaoXia Qian

Yongqi Deng

Wanying Sun

Yaolin Wang

Latha G Nair

Petr Vachal

Weidong Pan

Lehua Chang

Wei Deng

Guizhen Dong

Jiaqiang Cai

Debra L Ondeyka

Nam Fung Kar

Liya Chen

Graham Frank Smith

Kake Zhao

Christopher R Moyes

Chaomin Li

Xiaoxing Du

Richard Beresis

Dawn Marie Hoffman

Dietrich P Steinhuebel

Jayanth Thiruvellore Thatai

Jennifer Kowalchick

Luis Torres

Chandra Sekhar Korapala

Prashant R Latthe

Vyjayanthi N Kambam

Sujit Kumar Sarkar

Samantha E Adamson

Gayle E Hallett

Gergori J Morriello

Xiaoxia Qian

Chonggang Wang

Amit Ashokro Kudale

Jagannath Panda

Anthappan Tony Kurissery

The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors

The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors

Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application. 

N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors

Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer. 

Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors

The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

2,6,7 substituted purines as HDM2 inhibitors

The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Substituted pyrrolopyrimidines as HDM2 inhibitors

The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

2,6,7,8 substituted purines as HDM2 inhibitors

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of &#x3b2;3-adrenoceptor.

Pyrrolidine derived beta 3 adrenergic receptor agonists

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, Ais a substituted phenyl group or indanyl group. Formula (I). 

Cyclic amine substituted oxazolidinone CETP inhibitor

The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Substituted imidazopyridines as HDM2 inhibitors

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a &#x2014;CH&#x2014;.

CETP inhibitors

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of &#x3b2;3-adrenoceptor. 

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, Aand A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring. 

Growing community of inventors

Arlington, MA, United States of America

Christopher Francis Thompson